About Neuraltus

Improving the Lives of People Living with Neurodegenerative Diseases

Neuraltus Pharmaceuticals, Inc., is a privately-held pharmaceutical company dedicated to the development of therapeutics to treat neurodegenerative diseases, such as Alzheimer’s disease (AD) and frontotemporal dementia (FTD).

Neuraltus team members are working to advance therapies that have the potential to make a difference in the lives of people living with these often-devastating neurological conditions. We combine world-class scientific expertise, a robust patent portfolio and a strong commitment to working with the patient community to develop innovative treatments. Neuraltus is configured as a “virtual” drug development organization. We have a network of experienced advisors and service providers to advance our development programs.

Neuraltus began operations in 2004 based on a broad technology portfolio and intellectual property assembled by the company founders. Neuraltus has received more than $55 million in financing from leading venture groups, including VantagePoint Capital Partners and Latterell Venture Partners, to support its research and drug development efforts.